4[1]Rupniak HT,Whelan RD,Hill BT.Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro.Int J Cancer 1983;32:7-12
5[2]Kim CK,Lim SJ.Recent progress in drug delivery systems for anticancer agents.Arch Pharm Res 2002; 25:229-239
6[3]Oussoren C,Storm G.Liposomes to target the lymphatics by subcutaneous administration.Adv Drug Deliv Rev 2001; 50:143-156
7[4]Ridge JA,Collin C,Bading JR,Hancock C,Conti PS,Daly JM,Raaf JH.Increased adriamycin levels in hepatic implants of rabbit Vx-2 carcinoma from regional infusion.Cancer Res 1988;48:4584-4587
8[5]Eksborg S,Cedermark BJ,Strandler HS.Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.Med Oncol Tumor Pharmacother 1985; 2:47-54
9[6]Hope MJ,Nayar R,Mayer LD,Cullis PR.Reduction of liposome size and preparation of unilamellar vesicles by extrusion techniques.In:Liposome Technology.Vol Ⅰ.1st ed.Gregoriadis ed,1993:123-131
10[7]Cullis PR,Hope MJ,Bally MB,Madden TD,Mayer LD,Fenske DB.Influence of pH gradients on the transbilayer transport of drugs,lipids,peptides and metal ions into large unilamellar vesicles.Biochim Biophys Acta 1997; 1331:187-211
